Navco Pharmaceuticals Inc.
NAV.V
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -32.56% | -6.52% | |||
| Depreciation & Amortization | -- | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -39.58% | -5.88% | |||
| Operating Income | 39.58% | 5.88% | |||
| Income Before Tax | 35.71% | -68.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 35.71% | -68.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 35.71% | -68.00% | |||
| EBIT | 39.58% | 5.88% | |||
| EBITDA | 38.33% | 0.00% | |||
| EPS Basic | 50.00% | -100.00% | |||
| Normalized Basic EPS | 0.00% | 0.00% | |||
| EPS Diluted | 50.00% | -100.00% | |||
| Normalized Diluted EPS | 0.00% | 0.00% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||